Skip to main content
Article
Human cytomegalovirus seropositivity is associated with decreased survival in glioblastoma patients.
Neuro-oncology Advances (2019)
  • Haidn Foster, Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, Washington.
  • Keenan Piper, Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, Washington.
  • Lisa DePledge, Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, Washington.
  • Hsin-Fang Li, Medical Data Research Center, Providence St. Joseph Health, Portland, Oregon.
  • James Scanlan, Swedish Center for Research and Innovation, Seattle, Washington.
  • Yoon Jae-Guen, Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, Washington.
  • Michael Boeckh, Fred Hutchinson Cancer Research Center
  • Charles Cobbs, Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, Washington.
Publication Date
May 1, 2019
DOI
10.1093/NOAJNL/VDZ020
Citation Information
Haidn Foster, Keenan Piper, Lisa DePledge, Hsin-Fang Li, et al.. "Human cytomegalovirus seropositivity is associated with decreased survival in glioblastoma patients." Neuro-oncology Advances Vol. 1 Iss. 1 (2019)
Available at: http://works.bepress.com/hsin-fang-li/28/